Inclusion Criteria:

- Histologically confirmed persistent or recurrent squamous cell carcinoma (SCC) of the
cervix

- Patients must have received at least 1, but no more than 2, prior cytotoxic
chemotherapy regimens for advanced, metastatic, or recurrent SCC of the cervix

- Chemotherapy administered as a radio-sensitizer does not count as 1 regimen

- Documented disease progression

- At least 1 unidimensionally measurable lesion*

- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

- No tumor involving major blood vessels

- No history or physical evidence of CNS disease, including primary or metastatic brain
tumor

- Ineligible for a higher priority Gynecological Oncology Group (GOG) protocol (if one
exists), including any active GOG phase III protocol for the same patient population

- Performance status - GOG 0-2 (if received 1 prior regimen)

- Performance status - GOG 0-1 (if received 2 prior regimens)

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- No known bleeding disorder or coagulopathy

- No other active bleeding or pathologic condition that would confer a high risk of
bleeding

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- SGOT ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- INR ≤ 1.5 (or 2-3 for patients on a stable dose of therapeutic warfarin or low
molecular weight heparin)

- PTT < 1.2 times control

- Creatinine ≤ 1.5 times ULN

- Creatinine clearance > 60 mL/min

- No proteinuria

- Urine protein < 1+ on dipstick or < 30 mg/dL

- Urine protein < 1000 mg by 24-hour urine collection

- No clinically significant cardiovascular disease

- No uncontrolled hypertension

- No myocardial infarction or unstable angina within the past 6 months

- No New York Heart Association grade II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No grade II or greater peripheral vascular disease

- No history of stroke within the past 5 years

- No greater than grade 1 sensory or motor neuropathy

- No active infection requiring parenteral antibiotics

- No serious nonhealing wound, ulcer, or bone fracture

- No history or physical evidence of seizures not controlled with standard medical
therapy

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies

- No other invasive malignancy within the past 5 years except nonmelanomatous skin
cancer

- No significant traumatic injury within the past 4 weeks

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 3 months
after completion of study treatment

- No prior bevacizumab

- At least 3 weeks since prior immunologic agents for SCC of the cervix

- See Disease Characteristics

- Recovered from prior chemotherapy

- No prior non-cytotoxic chemotherapy for persistent or recurrent disease

- At least 1 week since prior hormonal therapy for SCC of the cervix

- Concurrent hormone replacement therapy allowed

- See Disease Characteristics

- Recovered from prior radiotherapy

- Recovered from recent prior surgery

- At least 4 weeks since prior major surgical procedure or open biopsy

- At least 1 week since prior placement of vascular access device or core biopsy

- No concurrent major surgical procedure

- At least 3 weeks since other prior therapy for SCC of the cervix

- No prior anticancer therapy that would preclude study therapy

- No concurrent anticoagulants other than those required to maintain the patency of
indwelling IV catheters

- No concurrent chronic daily aspirin greater than 325 mg/day or other nonsteroidal
anti-inflammatory medications that are known to inhibit platelet function at doses
used for chronic inflammatory diseases